Thus, the very low, often subnormal, levels of serum CS846 noted by Manson et al. [28] in RA patients with active joint destruction may indicate an inhibition of aggrecan synthesis or changes in the processes leading to CS846 release from tissues into body fluids. This evidence concerns the gene ACAN and rheumatoid arthritis.